BFM
BEAM icon

Boothbay Fund Management’s Beam Therapeutics BEAM Stock Holding History

Boothbay Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-394
Closed -$3.15M – 1846
2021
Q1 		$3.15M Buy
394
+152
+63% +$14.5K 0.12% 190
2020
Q4 		$1.98M Buy
+242
New +$11.9K 0.07% 270

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Boothbay Fund Management's BEAM Position: Q1 2026 in Review

Boothbay Fund Management sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 60,759 shares — an estimated $1.68M sold.

Boothbay Fund Management first reported a position in BEAM in Q3 2025 and held it in 2 quarters. The position peaked at $1.68M in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Boothbay Fund Management reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 60,759 Beam Therapeutics shares in Q1 2026, an estimated $1.68M.
  • Boothbay Fund Management first reported a position in Beam Therapeutics in Q3 2025 and held it in 2 quarters.
  • Boothbay Fund Management's Beam Therapeutics position peaked at $1.68M in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.